Ken O'Flynn
Portrait: © Houses of the Oireachtas (Oireachtas (Open Data) PSI Licence) · source file
Independent Ireland · Cork North-Central · serving since 2024-11-29
- Vote recorded in 265 of 401 divisions in the archive
- 401 debate contributions
- 8,232 parliamentary questions asked
Record timeline
- constituency Cork North-Central 2024-11-29 to present
- party Independent Ireland 2024-11-29 to present
written
2026-06-09 · to Health
1840. Deputy Ken O'Flynn asked the Minister for Health whether any estimate has been produced of the potential annual Exchequer cost associated with reimbursement of obesity pharmacotherapies under current licensing criteria. [41713/26]
written
2026-06-09 · to Health
1841. Deputy Ken O'Flynn asked the Minister for Health whether any national eligibility framework, prioritisation framework, or phased access model is under development for obesity pharmacotherapy reimbursement. [41714/26]
written
2026-06-09 · to Health
1842. Deputy Ken O'Flynn asked the Minister for Health whether multidisciplinary assessment, psychological screening, or behavioural intervention participation will be mandatory prior to reimbursement approval for obesity pharmacotherapies. [41715/26]
written
2026-06-09 · to Health
1843. Deputy Ken O'Flynn asked the Minister for Health whether any assessment has been undertaken of the long-term fiscal sustainability of reimbursing GLP-1 and dual agonist obesity therapies within the public health system. [41716/26]
written
2026-06-09 · to Health
1844. Deputy Ken O'Flynn asked the Minister for Health whether any formal safeguards or governance framework are being developed in relation to proposed reimbursement pathways for obesity pharmacotherapies in adolescent patients. [41717/26]
written
2026-06-09 · to Health
1845. Deputy Ken O'Flynn asked the Minister for Health whether any estimate has been produced of the projected number of adolescent patients who could potentially meet the proposed reimbursement criteria for semaglutide. [41718/26]
written
2026-06-09 · to Health
1850. Deputy Ken O'Flynn asked the Minister for Health to outline what the end-to-end process review will entail under Schedule 4 of the revised IPHA Framework Agreement; the expected terms of reference for the review; how stakeholders and members of the public will be able to feed into the review; and if she will make a statement on the matter. [41756/26]
written
2026-06-09 · to Health
1851. Deputy Ken O'Flynn asked the Minister for Health when she expects to publish the new diabetes strategy; and if she will make a statement on the matter. [41757/26]
written
2026-06-09 · to Health
1852. Deputy Ken O'Flynn asked the Minister for Health whether the HSE maintains any internal operational guidance, assessment template, decision-support document, evidential framework, or staff instruction document used in practice when determining eligibility under the treatment abroad scheme; and if so, if copies will be provided. [41759/26]
written
2026-06-09 · to Health
1853. Deputy Ken O'Flynn asked the Minister for Health whether any formal mechanism exists within the treatment abroad scheme to ensure consistency of eligibility decisions between applicants presenting with comparable clinical circumstances; and if they will outline that mechanism. [41760/26]
written
2026-06-09 · to Health
1854. Deputy Ken O'Flynn asked the Minister for Health whether any internal audit, external audit, clinical governance review, or value-for-money review has examined treatment abroad scheme eligibility decision-making processes since 2020; and if so, to provide details and publication status. [41761/26]
written
2026-06-09 · to Health
1855. Deputy Ken O'Flynn asked the Minister for Health whether the HSE maintains written evidential thresholds or documentary standards required before prior authorisation may be approved under the treatment abroad scheme; and if they will provide details. [41762/26]
written
2026-06-09 · to Health
1856. Deputy Ken O'Flynn asked the Minister for Health whether treatment abroad scheme approval decisions are subject to secondary review, peer review, multidisciplinary review, or independent oversight before final authorisation is granted. [41763/26]
written
2026-06-09 · to Health
1857. Deputy Ken O'Flynn asked the Minister for Health whether all categories of treatment funded under the treatment abroad scheme are subject to identical governance, evidential, audit, and approval standards; and if any category-specific governance arrangements exist. [41764/26]
written
2026-06-09 · to Health
1876. Deputy Ken O'Flynn asked the Minister for Health the total expenditure on agency staffing within the public health service for each year from 2020 to 2026 to date, broken down by HSE health region, staff category, and service area; and if she will make a statement on the matter. [41834/26]
written
2026-06-09 · to Health
1877. Deputy Ken O'Flynn asked the Minister for Health the number of sanctioned but unfilled permanent posts currently being covered through agency staffing arrangements within each HSE health region, broken down by grade, discipline, and service area; and if she will make a statement on the matter. [41844/26]
written
2026-06-09 · to Health
1878. Deputy Ken O'Flynn asked the Minister for Health whether the HSE has established regional or national targets to reduce agency staffing expenditure during 2026; if so, to provide details of those targets, timelines, and oversight mechanisms; and if she will make a statement on the matter. [41845/26]
written
2026-06-09 · to Health
1879. Deputy Ken O'Flynn asked the Minister for Health the proportion of agency staffing expenditure in 2026 to date attributable to agency engagements exceeding three months, six months, and twelve months respectively, broken down by HSE health region and staff category; and if she will make a statement on the matter. [41846/26]
written
2026-06-09 · to Health
1880. Deputy Ken O'Flynn asked the Minister for Health the total expenditure on agency staffing within section 38 and section 39 organisations funded by the HSE in 2026 to date, broken down by organisation type and staff category; and if she will make a statement on the matter. [41847/26]
written
2026-06-09 · to Health
1881. Deputy Ken O'Flynn asked the Minister for Health whether any HSE health region exceeded approved workforce or pay ceilings in 2025 or 2026 and subsequently relied on agency staffing arrangements to maintain operational capacity; and if she will make a statement on the matter. [41848/26]
written
2026-06-09 · to Health
1882. Deputy Ken O'Flynn asked the Minister for Health whether the HSE centrally monitors repeat agency usage by individual roles or locations; whether any risk assessments have been carried out regarding long-term dependence on agency staffing in frontline services; and if she will make a statement on the matter. [41849/26]
written
2026-06-09 · to Health
1883. Deputy Ken O'Flynn asked the Minister for Health whether the HSE has conducted any value-for-money analysis comparing long-term agency staffing expenditure against the cost of direct permanent recruitment for equivalent posts; and if she will make a statement on the matter. [41850/26]
written
2026-06-09 · to Health
1884. Deputy Ken O'Flynn asked the Minister for Health whether the HSE maintains data on agency staffing expenditure by hospital or facility level within each Health Region; and if she will provide the highest-spending sites in 2025 and 2026 to date. [41851/26]
written
2026-06-09 · to Health
1885. Deputy Ken O'Flynn asked the Minister for Health whether any internal audits, reviews, or reports have been completed since 2024 regarding agency staffing expenditure, procurement controls, or compliance with national workforce policies; and if she will make a statement on the matter. [41852/26]
written
2026-06-09 · to Health
1896. Deputy Ken O'Flynn asked the Minister for Health whether the HSE maintains a central register of all non-statutory bodies receiving direct or indirect HSE funding; whether the register identifies intermediary funding arrangements; and if she will provide details. [41863/26]